ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has agreed to acquire the antiviral therapy developer ReViral for up to $525 million, plus possible milestone payments. The British firm’s lead product is sisunatovir, a small molecule that targets the respiratory syncytial virus and is in Phase 2 clinical studies. ReViral was cofounded a decade ago by Stuart Cockerill, an organic chemist who earlier invented the GlaxoSmithKline cancer treatment Tykerb.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter